TY - JOUR
T1 - Fosmidomycin biosynthesis diverges from related phosphonate natural products
AU - Parkinson, Elizabeth I.
AU - Erb, Annette
AU - Eliot, Andrew C.
AU - Ju, Kou San
AU - Metcalf, William W.
N1 - Funding Information:
We thank M. Goettge and K. Wang for helpful discussions, X. Guan for his assistance with NMR experiments, Z. Li for his assistance with HRMS experiments, the UIUC Core Sequencing Facility for sequencing and P. Hergenrother (Chemistry Department, UIUC) for providing strains. This work was funded by the National Institutes of Health (grant nos. P01 GM077596 and R01GM127659 to W.W.M. and F32GM120999 to E.I.P.). NMR spectra were recorded on an instrument purchased with support from NIH grant no. S10 RR028833.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Fosmidomycin and related molecules comprise a family of phosphonate natural products with potent antibacterial, antimalarial and herbicidal activities. To understand the biosynthesis of these compounds, we characterized the fosmidomycin producer, Streptomyces lavendulae, using biochemical and genetic approaches. We were unable to elicit production of fosmidomycin, instead observing the unsaturated derivative dehydrofosmidomycin, which we showed potently inhibits 1-deoxy-d-xylulose-5-phosphate reductoisomerase and has bioactivity against a number of bacteria. The genes required for dehydrofosmidomycin biosynthesis were established by heterologous expression experiments. Bioinformatics analyses, characterization of intermediates and in vitro biochemistry show that the biosynthetic pathway involves conversion of a two-carbon phosphonate precursor into the unsaturated three-carbon product via a highly unusual rearrangement reaction, catalyzed by the 2-oxoglutarate dependent dioxygenase DfmD. The required genes and biosynthetic pathway for dehydrofosmidomycin differ substantially from that of the related natural product FR-900098, suggesting that the ability to produce these bioactive molecules arose via convergent evolution.
AB - Fosmidomycin and related molecules comprise a family of phosphonate natural products with potent antibacterial, antimalarial and herbicidal activities. To understand the biosynthesis of these compounds, we characterized the fosmidomycin producer, Streptomyces lavendulae, using biochemical and genetic approaches. We were unable to elicit production of fosmidomycin, instead observing the unsaturated derivative dehydrofosmidomycin, which we showed potently inhibits 1-deoxy-d-xylulose-5-phosphate reductoisomerase and has bioactivity against a number of bacteria. The genes required for dehydrofosmidomycin biosynthesis were established by heterologous expression experiments. Bioinformatics analyses, characterization of intermediates and in vitro biochemistry show that the biosynthetic pathway involves conversion of a two-carbon phosphonate precursor into the unsaturated three-carbon product via a highly unusual rearrangement reaction, catalyzed by the 2-oxoglutarate dependent dioxygenase DfmD. The required genes and biosynthetic pathway for dehydrofosmidomycin differ substantially from that of the related natural product FR-900098, suggesting that the ability to produce these bioactive molecules arose via convergent evolution.
UR - http://www.scopus.com/inward/record.url?scp=85071455235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071455235&partnerID=8YFLogxK
U2 - 10.1038/s41589-019-0343-1
DO - 10.1038/s41589-019-0343-1
M3 - Article
C2 - 31451762
AN - SCOPUS:85071455235
SN - 1552-4450
VL - 15
SP - 1049
EP - 1056
JO - Nature chemical biology
JF - Nature chemical biology
IS - 11
ER -